David Philip Bissig, MD
Neurology · Sacramento
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 2
- Since medical school
- 12 years
- Wayne State University School of Medicine, 2014
Offices
2 locations · Regents of the University of California · Regents of the Univ of CA
Hospitals listed: University of California Davis Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Bissig’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A140344 · Current
Licensed to practise in California · since 2016 · expires 2027-12-31 · Wayne State University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Psychiatry and Neurology - Neurology
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- University of California Davis Medical CenterSacramento, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of UC Davis Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Abdominopelvic accidental puncture or laceration rate: 1.94 (1.18 to 2.71) · 3,010 cases, Jul 2022 – Jun 2024Worse than the national rate — MRSA Bacteremia: 1.564, Oct 2024 – Sep 2025Worse than the national rate — Rate of emergency department (ED) visits for patients receiving outpatient chemotherapy: 6.7 (5.6 to 8) · 1,134 cases, Jan 2024 – Dec 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.6 (10.9 to 14.5) · 1,134 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 127.46 (95.81 to 159.1) · 281 cases, Jul 2022 – Jun 2024Better than the national rate — Pressure ulcer rate: 0.18 (0 to 0.57) · 12,625 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.677, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.713, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 1) · 2,436 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for University of California Davis Medical Center
Behind the star rating — Deaths: 4 better, 4 the same, 0 worse of 8 measures. Safety: 0 better, 7 the same, 1 worse of 8 measures. Readmissions: 0 better, 9 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.94 (1.18 to 2.71) · 3,010 cases | Worse | Jul 2022 – Jun 2024 |
| MRSA BacteremiaInfections | 1.564 | Worse | Oct 2024 – Sep 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.7 (5.6 to 8) · 1,134 cases | Worse | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.6 (10.9 to 14.5) · 1,134 cases | Worse | Jan 2024 – Dec 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 127.46 (95.81 to 159.1) · 281 cases | Better | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.18 (0 to 0.57) · 12,625 cases | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.677 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.713 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.7 to 1) · 2,436 cases | Better | Jan 2024 – Dec 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.98 (0.78 to 1.19) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.2 · 82 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.2 · 165 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.2 · 115 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.7 · 662 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.1 · 463 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 406 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 4,328 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.22 (0.05 to 0.39) · 13,828 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.3 (0.13 to 0.46) · 14,152 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.29 (2.92 to 5.66) · 4,920 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.78 (0.46 to 3.09) · 2,250 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.07 (1.06 to 3.09) · 4,696 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.46 (5.18 to 13.75) · 2,102 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.35 (3.74 to 8.96) · 2,191 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.48 (1.19 to 3.77) · 1,169 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.3 · 127 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.826 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.899 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.669 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.2 · 131 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.2 · 751 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -25.8 · 127 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 24.1 · 758 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 23.6 · 477 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.6 · 469 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 140 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 65 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 18.3 · 203 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 11.8 (9.4 to 14.9) · 2,643 cases | No different | Jan 2022 – Dec 2024 |
What patients said (2,768 patients answered, 18% of those asked)
| Cleanliness | 2 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 1 |
| Recommend hospital | 4 |
| Room was "always" clean | 61% |
| Nurses "always" communicated well | 76% |
| Doctors "always" communicated well | 78% |
| Staff "always" explained | 60% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 72% |
| Doctors "always" listened carefully | 76% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 68% |
| Staff "always" explained new medications | 73% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 37% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 47% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$44,751
Medicare paid this office $44,751 for 300 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 131 | $19,290 | $130 |
| Return visit (30+ min) | 95 | $8,689 | $85 |
| New patient visit (60+ min) | 32 | $5,101 | $159 |
| New patient visit (45+ min) | 18 | $1,972 | $110 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 44 | $1,564 | $26 |
See all 10 services
| Long return visit (40+ min) | 131 | $19,290 | $130 |
| Return visit (30+ min) | 95 | $8,689 | $85 |
| New patient visit (60+ min) | 32 | $5,101 | $159 |
| New patient visit (45+ min) | 18 | $1,972 | $110 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 44 | $1,564 | $26 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 90 | $1,208 | $13 |
| Short return visit (20+ min) | 19 | $1,187 | $59 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 11 | $1,146 | $64 |
| Influenza vaccine split virus, preservative free | 13 | $1,054 | $81 |
| Administration of influenza virus vaccine | 14 | $478 | $34 |
Who their Medicare patients are
300 Original Medicare patients in 2024. Average age 76 · Under 65 8% · 85 and older 15% · Women 53% · Also on Medicaid 20% · Health risk score 1.57. At or below the middle of the specialty; the typical neurology clinician is at 1.61.
Conditions among them: High blood pressure 66% · Dementia 61% · Depression 40% · Diabetes 26% · Coronary heart disease 26% · Chronic kidney disease 23% · Atrial fibrillation 20% · Stroke 19% · Heart failure 15% · COPD 14% · Cancer 13%.
The office billed $236,773, Medicare allowed $63,191 and paid $44,751; for 569 services of 29 kinds; $1,076 of it was for drugs given in the office and $43,675 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 300 | 569 | 76 | 1.57 | $236,773 | $44,751 |
| 2023 | 373 | 553 | 76 | 1.62 | $281,551 | $51,441 |
| 2022 | 638 | 1,068 | 76 | 1.46 | $566,102 | $117,912 |
| 2021 | 509 | 883 | 76 | 1.55 | $433,336 | $99,459 |
| 2020 | 145 | 179 | 74 | 1.85 | $84,898 | $16,398 |
| 2019 | 50 | 90 | 74 | 1.34 | $23,233 | $6,953 |
| 2018 | 20 | 35 | 74 | 0.81 | $5,784 | $3,289 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 7 services
| Long return visit (40+ min) | 148 | $22,445 | $132 |
| Return visit (30+ min) | 133 | $11,114 | $78 |
| New patient visit (60+ min) | 32 | $4,899 | $153 |
| New patient visit (45+ min) | 28 | $3,081 | $110 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 39 | $1,643 | $27 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 13 | $1,383 | $66 |
| Short return visit (20+ min) | 16 | $1,017 | $64 |
2022: 14 services
| Long return visit (40+ min) | 264 | $42,368 | $144 |
| New patient visit (60+ min) | 194 | $33,159 | $171 |
| Return visit (30+ min) | 179 | $19,891 | $99 |
| New patient visit (45+ min) | 28 | $3,390 | $121 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 94 | $3,047 | $27 |
| Evaluation of neuropsychological test, first hour | 22 | $2,239 | $102 |
| Exam of neurobehavioral status, first hour | 31 | $1,748 | $56 |
| Extended patient service without direct patient contact, first hour | 16 | $1,536 | $90 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 16 | $1,168 | $58 |
| Short return visit (20+ min) | 17 | $1,026 | $57 |
| Influenza vaccine split virus, preservative free | 15 | $1,008 | $67 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 12 | $982 | $82 |
| Administration of influenza virus vaccine | 17 | $539 | $32 |
| Administration of psychological or neuropsychological test, first 30 minutes | 12 | $317 | $26 |
2021: 13 services
| New patient visit (60+ min) | 220 | $39,055 | $178 |
| Long return visit (40+ min) | 163 | $28,875 | $145 |
| Long return visit (40+ min) | 44 | $5,498 | $115 |
| Return visit (30+ min) | 32 | $2,941 | $92 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 65 | $2,549 | $27 |
| New patient visit (60+ min) | 14 | $1,915 | $137 |
| New patient visit (45+ min) | 17 | $1,787 | $105 |
| Evaluation of neuropsychological test, first hour | 14 | $1,572 | $112 |
| Influenza vaccine split virus, preservative free | 21 | $1,370 | $65 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 12 | $1,358 | $113 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 15 | $1,254 | $84 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 37 | $1,066 | $26 |
| Administration of influenza virus vaccine | 21 | $384 | $18 |
2020: 6 services
| Long return visit (40+ min) | 46 | $4,002 | $87 |
| New patient visit (60+ min) | 25 | $3,126 | $125 |
| Long return visit (40+ min) | 20 | $1,863 | $93 |
| New patient visit (45+ min) | 13 | $1,394 | $107 |
| Extended office or other outpatient service, first hour | 15 | $1,262 | $84 |
| Return visit (30+ min) | 11 | $461 | $42 |
2019: 2 services
| Long return visit (40+ min) | 12 | $940 | $78 |
| Return visit (30+ min) | 11 | $635 | $58 |
2018: 1 service
| Extended office or other outpatient service, first hour | 12 | $941 | $78 |
Drugs they prescribed that Part D paid
$64,329
Pharmacies billed $64,329 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 1,015) in 2024. At or below the middle of the specialty; the typical neurology clinician is at 0%.
985 generic and 30 brand-name prescriptions · $64,329 in drug cost · 46 antipsychotic prescriptions to people over 65.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Rivastigmine | 23 | $5,896 | $256 |
| Memantine | 107 | $5,768 | $54 |
| Donepezil | 361 | $5,436 | $15 |
| Doxepin | 27 | $4,087 | $151 |
| Galantamine Hbr | 47 | $3,623 | $77 |
See all 20 drugs
| Rivastigmine | 23 | $5,896 | $256 |
| Memantine | 107 | $5,768 | $54 |
| Donepezil | 361 | $5,436 | $15 |
| Doxepin | 27 | $4,087 | $151 |
| Galantamine Hbr | 47 | $3,623 | $77 |
| Carbidopa-Levodopa Er | 15 | $2,936 | $196 |
| Carbidopa-Levodopa | 38 | $1,324 | $35 |
| Trazodone | 57 | $875 | $15 |
| Rivastigmine | 11 | $843 | $77 |
| Quetiapine | 23 | $714 | $31 |
| Mirtazapine | 31 | $681 | $22 |
| Escitalopram | 30 | $597 | $20 |
| Sertraline | 52 | $474 | $9 |
| Lamotrigine | 18 | $469 | $26 |
| Duloxetine | 11 | $320 | $29 |
| Gabapentin | 16 | $227 | $14 |
| Dextroamphetamine-Amphetamine | 11 | $196 | $18 |
| Risperidone | 17 | $171 | $10 |
| Citalopram Hbr | 11 | $106 | $10 |
| Fluoxetine | 11 | $96 | $9 |
Year by year
| 2024 | 1,015 | 230 | 0% (0) | 3% | $64,329 |
| 2023 | 1,540 | 299 | 0% (0) | 3% | $105,220 |
| 2022 | 1,817 | 347 | 0% (0) | 3% | $216,044 |
| 2021 | 882 | 208 | 0% (0) | 2% | $32,537 |
| 2020 | 280 | 71 | 0% (0) | None | $10,800 |
| 2019 | 306 | 58 | 0% (0) | 8% | $19,453 |
| 2018 | 392 | 69 | 0% (0) | None | $136,499 |
| 2017 | 388 | 54 | 0% (0) | 16% | $76,134 |
| 2016 | 177 | 26 | None | 12% | $12,865 |
| 2015 | 21 | None | None | None | $2,098 |
| 2014 | 16 | None | 0% (0) | None | $532 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 19 drugs
| Rivastigmine | 55 | $16,165 | $294 |
| Donepezil | 529 | $11,265 | $21 |
| Memantine | 216 | $10,810 | $50 |
| Doxepin | 27 | $7,426 | $275 |
| Galantamine Hbr | 65 | $5,711 | $88 |
| Carbidopa-Levodopa | 85 | $5,172 | $61 |
| Memantine Hcl Er | 13 | $4,771 | $367 |
| Carbidopa-Levodopa Er | 12 | $4,075 | $340 |
| Rivastigmine | 24 | $2,162 | $90 |
| Mirtazapine | 48 | $1,645 | $34 |
| Venlafaxine Hcl Er | 12 | $1,554 | $129 |
| Trazodone | 89 | $1,357 | $15 |
| Gabapentin | 34 | $1,234 | $36 |
| Sertraline | 82 | $914 | $11 |
| Quetiapine | 34 | $896 | $26 |
| Levetiracetam | 14 | $693 | $49 |
| Bupropion Xl | 13 | $210 | $16 |
| Risperidone | 21 | $200 | $10 |
| Escitalopram | 15 | $191 | $13 |
2022: 19 drugs
| Ingrezza | 12 | $96,457 | $8,038 |
| Rivastigmine | 73 | $20,756 | $284 |
| Memantine | 247 | $13,058 | $53 |
| Galantamine Hbr | 97 | $11,444 | $118 |
| Donepezil | 648 | $11,148 | $17 |
| Carbidopa-Levodopa | 112 | $6,138 | $55 |
| Myrbetriq | 11 | $5,259 | $478 |
| Rivastigmine | 31 | $2,518 | $81 |
| Trazodone | 132 | $1,846 | $14 |
| Gabapentin | 49 | $1,639 | $33 |
| Levetiracetam | 18 | $1,418 | $79 |
| Quetiapine | 62 | $1,415 | $23 |
| Mirtazapine | 32 | $1,133 | $35 |
| Bupropion Hcl Sr | 13 | $819 | $63 |
| Sertraline | 91 | $792 | $9 |
| Duloxetine | 20 | $583 | $29 |
| Quetiapine Fumarate Er | 11 | $271 | $25 |
| Olanzapine | 12 | $198 | $16 |
| Bupropion Xl | 18 | $160 | $9 |
2021: 16 drugs
| Myrbetriq | 15 | $6,197 | $413 |
| Memantine | 84 | $4,866 | $58 |
| Donepezil | 345 | $4,265 | $12 |
| Galantamine Hbr | 49 | $3,511 | $72 |
| Carbidopa-Levodopa | 37 | $2,230 | $60 |
| Rivastigmine | 22 | $1,605 | $73 |
| Venlafaxine Hcl Er | 13 | $1,469 | $113 |
| Trazodone | 66 | $639 | $10 |
| Mirtazapine | 12 | $558 | $47 |
| Levetiracetam | 11 | $505 | $46 |
| Sertraline | 81 | $413 | $5 |
| Bupropion Xl | 13 | $402 | $31 |
| Duloxetine | 13 | $395 | $30 |
| Bupropion Hcl Sr | 17 | $308 | $18 |
| Quetiapine | 18 | $194 | $11 |
| Gabapentin | 12 | $52 | $4 |
2020: 6 drugs
| Memantine | 51 | $2,013 | $39 |
| Carbidopa-Levodopa | 12 | $991 | $83 |
| Donepezil | 81 | $902 | $11 |
| Sertraline | 56 | $465 | $8 |
| Gabapentin | 11 | $155 | $14 |
| Mirtazapine | 11 | $105 | $10 |
2019: 6 drugs
| Memantine | 65 | $2,130 | $33 |
| Ondansetron | 11 | $1,183 | $108 |
| Donepezil | 63 | $644 | $10 |
| Carbidopa-Levodopa | 19 | $628 | $33 |
| Sertraline | 39 | $259 | $7 |
| Gabapentin | 12 | $113 | $9 |
2018: 11 drugs
| Copaxone | 12 | $74,542 | $6,212 |
| Carbamazepine Er | 15 | $2,815 | $188 |
| Levetiracetam | 27 | $879 | $33 |
| Memantine | 13 | $612 | $47 |
| Gabapentin | 35 | $496 | $14 |
| Atorvastatin | 17 | $351 | $21 |
| Baclofen | 20 | $296 | $15 |
| Donepezil | 41 | $291 | $7 |
| Carbidopa-Levodopa | 21 | $252 | $12 |
| Lidocaine-Prilocaine | 13 | $246 | $19 |
| Quetiapine | 15 | $76 | $5 |
2017: 15 drugs
| Carbamazepine Er | 21 | $3,623 | $173 |
| Sumatriptan | 12 | $909 | $76 |
| Levocarnitine | 12 | $434 | $36 |
| Levetiracetam | 13 | $353 | $27 |
| Baclofen | 25 | $325 | $13 |
| Cyclobenzaprine | 13 | $254 | $20 |
| Topiramate | 15 | $251 | $17 |
| Carbidopa-Levodopa | 15 | $232 | $15 |
| Atorvastatin | 11 | $213 | $19 |
| Donepezil | 32 | $159 | $5 |
| Propranolol | 12 | $145 | $12 |
| Gabapentin | 12 | $119 | $10 |
| Divalproex | 24 | $116 | $5 |
| Lamotrigine | 12 | $77 | $6 |
| Lorazepam | 13 | $25 | $2 |
2016: 4 drugs
| Carbamazepine Er | 13 | $1,449 | $111 |
| Atorvastatin | 20 | $429 | $21 |
| Donepezil | 15 | $78 | $5 |
| Verapamil Er | 13 | $63 | $5 |
Professional record
- NPI
- 1144648338
- Licence
- CA A140344, OR MD186924California A140344: Current · expires 2027-12-31
- Trained
- Wayne State University School of Medicine, 2014 · 12 years ago
- Group
- Regents of the University of California · Regents of the Univ of CA
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Neurology (2084N0400X)
- Mailing address
- 3160 Folsom Blvd, Sacramento, CA, 95816
- NPI first listed
- 2014-04-03
- NPI last updated
- 2021-10-26
- NPI record certified
- 2021-10-26
This is when the NPI record was last certified, not a medical board exam.